- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | ZyVersa Therapeutics wechselt in den OTCQB Venture Market | 2 | Investing.com Deutsch | ||
| Mo | ZyVersa Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.07. | ZyVersa secures $12 million in financing to advance kidney disease trials | 1 | Investing.com | ||
| 21.07. | ZyVersa sichert sich 12-Millionen-Dollar-Finanzierung für Nierenstudien | 2 | Investing.com Deutsch | ||
| 21.07. | ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress | 100 | GlobeNewswire (Europe) | WESTON, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment... ► Artikel lesen | |
| 18.07. | ZyVersa Therapeutics, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 16.07. | ZyVersa Therapeutics vor NASDAQ-Delisting - Aktie wechselt in den OTC-Handel | 7 | Investing.com Deutsch | ||
| 09.07. | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| ZYVERSA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.07. | ZyVersa Secures $2 Mln Through Warrant Inducement Deal With Institutional Investor | 1 | RTTNews | ||
| 08.07. | Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday? | 3 | Benzinga.com | ||
| 08.07. | ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds | 2 | GlobeNewswire (USA) | ||
| 08.07. | ZyVersa erhält FDA-Notfallzulassung für VAR 200 bei seltener Nierenerkrankung | 3 | Investing.com Deutsch | ||
| 08.07. | ZyVersa's VAR 200 approved for emergency use in rare kidney disease | 1 | Investing.com | ||
| 08.07. | ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator VAR 200 in a Patient with ApoCII Amyloidosis | 476 | GlobeNewswire (Europe) | ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into... ► Artikel lesen | |
| 02.07. | ZyVersa Therapeutics, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 26.06. | ZyVersa beginnt mit Patientenrekrutierung für Nierenerkrankung-Medikamentenstudie | 3 | Investing.com Deutsch | ||
| 26.06. | ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD) | 165 | GlobeNewswire (Europe) | Initiation of patient recruitment marks a key milestone in the development of VAR 200, a potential first-in-class treatment for kidney disease addressing renal lipotoxicity.There are no available... ► Artikel lesen | |
| 25.06. | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.06. | ZyVersa schließt Aktienrückkaufvereinbarung über 10 Millionen US-Dollar mit WVH ab | 4 | Investing.com Deutsch | ||
| 25.06. | ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator VAR 200 | 2 | GlobeNewswire (USA) |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,180 | -0,24 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
| EVOTEC | 7,378 | -0,30 % | Evotec Aktie unter der Lupe - Abivax, Bayer, Rheinmetall, Sartorius und Suss MicroTec im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 30,060 | -1,12 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 36,880 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory ... | -- Topline data readout from HARBOR study anticipated in Q2 2026 ---- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,805 | 0,00 % | Recursion Pharmaceuticals: Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th | ||
| IMMUNOME | 10,750 | +1,18 % | Immunome Inc. - 8-K, Current Report | ||
| BEAM THERAPEUTICS | 20,140 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,590 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025 | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 50,56 | 0,00 % | ROUNDUP/Aktien New York Schluss: Gewinne - Arbeitsmarktdaten stützen | NEW YORK (dpa-AFX) - Die New Yorker Börsen haben am Dienstag nach einem verhaltenen Start ihre Kursgewinne ausgebaut. Marktbeobachter verwiesen darauf, dass die jüngsten Daten vom US-Arbeitsmarkt trotz... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 6,900 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 | - Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 56,61 | +1,16 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies | The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,660 | 0,00 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
| PTC THERAPEUTICS | 41,800 | +1,46 % | XFRA BH3: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPTC THERAPEUTICS... ► Artikel lesen | |
| COGENT BIOSCIENCES | 11,540 | -2,45 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced ... | -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared... ► Artikel lesen | |
| CG ONCOLOGY | 26,950 | +3,49 % | CG Oncology wins Delaware jury trial against ANI Pharmaceuticals |
ZYVERSA THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,001 (-0,42 %) liegt der Kurs bei 0,310 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZYVERSA THERAPEUTICS INC finden Sie auf Wallstreet Online.